Waisman Biomanufacturing helps bring UMass Medical School HIV vaccine to Phase I trial

Waisman Biomanufacturing has produced and helped bring to clinical trial a vaccine that aims to prevent infection by the human immunodeficiency virus (HIV), which causes AIDS.

The vaccine was developed by researchers at the University of Massachusetts Medical School and is set to undergo a Phase I clinical trial at four sites in the United States.

Read the full article at: https://www.umassmed.edu/news/news-archives/2018/03/umass-medical-school-hiv-vaccine-to-be-tested-in-new-phase-i-trial/